The Bioprocessing Industry Has A Digital Execution Problem

By Martin Ball, Sr. Product Marketing Manager, Automation and Digital, Cytiva

Biopharma innovation is moving quickly, but digital execution has not kept pace. Many organizations remain early in their transformation, while others struggle to scale new capabilities across disconnected teams, workflows, and manufacturing stages. The result is limited visibility, fragmented data, manual decision-making, and slower progress toward operational goals. As therapies become more complex and personalized, these gaps can increase costs, weaken competitiveness, and delay time-to-market. Success will depend not simply on adopting advanced technologies, but on building confidence in digital systems and integrating them into daily operations.

See why execution has become a critical differentiator and how manufacturers can create more efficient, predictable processes that help deliver therapies to patients sooner.